| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 01/05/2005 | EP1492512A1 Method for systemic drug delivery through the nail |
| 01/05/2005 | EP1492419A1 Use of creatine pyruvate for increasing stamina during highly intensive intermittent physical exertion |
| 01/05/2005 | EP1420643A4 Enhancement of transfection of dna into the liver |
| 01/05/2005 | EP1282414B1 Felbamate derived compounds for treating neuropathic pain |
| 01/05/2005 | EP1274687B1 1,2,3,4- tetrahydroisoquinoline derivatives |
| 01/05/2005 | EP1239837B1 Direct compression polymer tablet core |
| 01/05/2005 | EP1226126B1 Pyrimidine derivatives |
| 01/05/2005 | DE19957065B4 Screening-Verfahren für Arzneistoffe A screening method for drugs |
| 01/05/2005 | DE10327439A1 Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel New Imidazopyridazinon- and Imidazopyridonderivate, their preparation and their use as medicaments |
| 01/05/2005 | CN1561393A Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma |
| 01/05/2005 | CN1561387A Probiotic bifidobacterium strains |
| 01/05/2005 | CN1561344A Angiogenesis-inhibitory tripeptides, compositions and their methods of use |
| 01/05/2005 | CN1561343A Soluble T cell receptor |
| 01/05/2005 | CN1561231A Inhibition of neonatal hyperbilirubinemia in breast fed infants |
| 01/05/2005 | CN1561226A Use of the long pentraxin PTX3 for the preparation of medicament for the prevention and cure of autoimmune pathologies |
| 01/05/2005 | CN1561223A New drug |
| 01/05/2005 | CN1561219A Pharmaceutical compounds |
| 01/05/2005 | CN1561216A Novel compounds |
| 01/05/2005 | CN1561215A Salts of substituted 1, 2, 3, 4-tetrahydroquinoline-2-carboxylic acid compounds used as nmda antagonist |
| 01/05/2005 | CN1561214A New formulations and use thereof |
| 01/05/2005 | CN1561213A New formulations and use thereof |
| 01/05/2005 | CN1561211A Nociceptin analogs |
| 01/05/2005 | CN1561201A Pharmaceutical compositions comprising colloidal silicon dioxide |
| 01/05/2005 | CN1561199A Pharmaceutical composition comprising lipids comprising a polar and a nonpolar moiety |
| 01/05/2005 | CN1560249A Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity |
| 01/05/2005 | CN1560080A Corpuscles of stannius protein, stanniocalcin |
| 01/05/2005 | CN1560061A Process for extracting dioscored soap oside from dioscorea |
| 01/05/2005 | CN1560032A Sultonyl (thio)urea derivants, their preparation process and pharmaceutical composition containing them |
| 01/05/2005 | CN1560024A Composite of functional fatty acid, amino acid and preparation process thereof |
| 01/05/2005 | CN1559605A Compound aloe health-care tablet |
| 01/05/2005 | CN1559603A Hunai Mushroom sclerotium used for treating diabotes and its preparation |
| 01/05/2005 | CN1559582A Natural calcium supplementing powder |
| 01/05/2005 | CN1559570A Natural nutritive liquid and its preparation method |
| 01/05/2005 | CN1559561A Nucleic acid gene chinese and western medicinal product both for medicine and food used for preventing and curing poultry animal and human being grippe and its manufacturing method |
| 01/05/2005 | CN1559549A Medicine for treating diabetes and its preparation method |
| 01/05/2005 | CN1559539A Medicinal mixture possessing alpha glycocidase inhibiting activity and its use |
| 01/05/2005 | CN1559538A Compound Chinese medicinal extract mixture and its prepration method |
| 01/05/2005 | CN1559537A Health-care food capsule capable of detoxification and fat lowering and its preparation method |
| 01/05/2005 | CN1559491A Substance possessing sugarreducing action extracted from furmeric |
| 01/05/2005 | CN1559443A Sturgeon chondroition capsule and instant granula prepn. method therefor |
| 01/05/2005 | CN1559442A Soft capsule of dried oviduct fat of forest frog |
| 01/05/2005 | CN1559437A Oral Liquid-supplement salt quick-dissolving tablets, prepn. method therefor |
| 01/05/2005 | CN1559436A Oral liquid-supplement salt flash-dissloving tablets, and prepn. method therefor |
| 01/05/2005 | CN1559435A Oral liqid-supplement salt effervesce tablets, and prepn. method therefor |
| 01/05/2005 | CN1559434A Oral liquid-supplement salt disperson tablets, and prepn. method therefor |
| 01/05/2005 | CN1559405A Solid prepn. of sodium vitamin C for injection and its prepn. method |
| 01/05/2005 | CN1559399A Injection of haw leaf flavone prepn. method and use thereof |
| 01/05/2005 | CN1559394A Compound prepn. for lowering blood-sugar, and its use |
| 01/05/2005 | CN1559385A Probucol solid dispersion tablets, and prepn. method therefor |
| 01/05/2005 | CN1183158C Exendin analogue, processes for their preparation and medicaments containing them |
| 01/05/2005 | CN1183148C Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium 2.5 hydrate or monohydrate |
| 01/05/2005 | CN1183136C Indoloquinazolinones |
| 01/05/2005 | CN1183132C Tetracyclic azepinoindole compounds as 5-HT receptor ligands |
| 01/05/2005 | CN1183130C Thiazolidine derivatives and medicinal application thereof |
| 01/05/2005 | CN1183122C Dipeptide nitrile cathepsin K inhibitors |
| 01/05/2005 | CN1183116C Substituted isoquinoline derivatives and pharmaceutical composition containing them, its preparation method and use |
| 01/05/2005 | CN1183113C Tri-aryl acid derivatives as PPAR receptor ligands |
| 01/05/2005 | CN1183111C Cycloalkano-indole and cycloalkane-azaindole derivatives, process for their preparation and pharmaceutical commposition containing the same |
| 01/05/2005 | CN1182874C Gene therapy for diabetic ischemic disease |
| 01/05/2005 | CN1182873C Arginine silicate inositol complex and use thereof |
| 01/05/2005 | CN1182861C Medicines for treating and preventing diabetes and nephrodystrophy and its preparation method |
| 01/05/2005 | CN1182850C Preparation capable of regulating blood fat, blood pressure and blood sugar for protecting heart and brain cells and its prearing method |
| 01/05/2005 | CN1182844C Use of dialkylfumarates |
| 01/04/2005 | US6838584 Estrogen receptor modulators |
| 01/04/2005 | US6838574 Induction cell differentiation; leukemia therapy |
| 01/04/2005 | US6838559 Such as 2-((6-(((4-(3,4-dimethoxyphenyl)methyl)amino)-7-ethyl-7H-purin-2-yl)amino) -4,5-methyl-N-phenyl-5-thiazole-carboxamide for treatment of lymphocyte mediated diseases such as transplant rejection and graft versus host disease |
| 01/04/2005 | US6838470 Antiischemic agents; brain disorders; cardiovascular disorders |
| 01/04/2005 | US6838466 Compounds for the treatment of inflammatory disorders |
| 01/04/2005 | US6838465 N-acyltetrahydroisoquinoline derivatives |
| 01/04/2005 | US6838461 Psychological disorders; schizophrenia; Alzheimer's disease; Parkinson's disease; Huntington's disease; cardiovascular disorders; hypotensive agents; side effect reduction |
| 01/04/2005 | US6838458 5-(alkylidene-cycloalkyl)-and 5-(alkylidene-heterocyclyl)-pyrazoles |
| 01/04/2005 | US6838442 Administering to said subject a jointly effective amount of a glucose reabsorption inhibitor; administering jointly effective amount of an retinoid-X receptor modulator for therapy of diabetes or Syndrome X |
| 01/04/2005 | US6838439 Heterocytes as inhibitors of leucocyte adhesion and as VLA-4 antagonists |
| 01/04/2005 | US6838274 Urocortin proteins and uses thereof |
| 01/04/2005 | US6838096 Black soybean polysaccharides |
| 01/04/2005 | US6838076 Pulmonary administration of chemically modified insulin |
| 01/04/2005 | CA2340999C 5-arylindole derivatives |
| 01/04/2005 | CA2251563C Method for maintaining an existing level of body fat and/or body weight |
| 12/30/2004 | US20040268440 Transgenic plants expressing cobalamin binding proteins |
| 12/30/2004 | US20040267028 Such as 2-amino-1-(2-chlorophenyl)-5-(4-chlorophenyl)-N-cyclohexyl-1H-pyrrole-3-carboxamide hydrochloride |
| 12/30/2004 | US20040267025 Compounds for the treatment of metabolic disorders |
| 12/30/2004 | US20040267016 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5) |
| 12/30/2004 | US20040267010 For therapy of central nervous system disorders |
| 12/30/2004 | US20040266879 Certain ethers of probucol, and their pharmaceutically acceptable salts or prodrugs, are useful for increasing circulating high density lipoprotein cholestrol |
| 12/30/2004 | US20040266864 Possess potent serotonin reuptake inhibitory activity, with minimal inhibitory effects on the reuptake of other known monoamines, e.g., norepinephrine or dopamine; also useful for treating or preventing other CNS disorders, cerebrovascular or vascular dysfunctions, sexual dysfunctiions, eating disorders |
| 12/30/2004 | US20040266845 Benzothiazolyl derivatives |
| 12/30/2004 | US20040266842 Thiazolyl substituted triazoles as alk5 inhibitors |
| 12/30/2004 | US20040266841 Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity |
| 12/30/2004 | US20040266839 2'-Methyl-5-(1,3,4-oxadiazol-2-yl)1,1'-biphenyl-4-carboxaide derivatives and their use as p38 kinase inhibitors |
| 12/30/2004 | US20040266836 Salt of acidic AT1-receptor antagonist and basic cardiovascular ingredient; potentiation or synergism; reduction of side effects |
| 12/30/2004 | US20040266830 Insulin sensitivity enhancer and second antidiabetic of different mechanism; suppressing hyperglycemia |
| 12/30/2004 | US20040266822 Secondary amines; tissue specificity; reduced side effects; cardiovascular diseases, diabetes, bronchial and urinary smooth muscle spasms, ischemia, anoxic nerve injury |
| 12/30/2004 | US20040266793 Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders |
| 12/30/2004 | US20040266789 Substituted amino carboxylic acids |
| 12/30/2004 | US20040266780 Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| 12/30/2004 | US20040266775 for human, veterinary, or phytoprotective use, e.g., inhibiting the cellular sodium-proton antiporter activity, for the treatment of cardiovascular diseases, metabolic diseases, cancerous diseases or fibrotic diseases |
| 12/30/2004 | US20040266750 Beta-lactamyl vasopressin v1aantagonists |
| 12/30/2004 | US20040266733 Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor Type-1 (PAI-1) |
| 12/30/2004 | US20040266682 administering gastrin/(cholecystokinin (CCK) receptor ligand and a factor for complementing gastrin for islet neogenesis therapy; sustained release; for expanding a functional beta cell mass of pancreatic islet transplants; reduces amount of stem cells necessary for treatment; kits |
| 12/30/2004 | US20040266678 Methods and compositions for treating polycystic ovary syndrome |